Perspective Therapeutics, Inc. CATX

CATX Company Overview

Perspective Therapeutics, Inc. (Nasdaq: CATX) is a U.S.-based radiopharmaceutical company focused on developing targeted alpha-particle therapies for the treatment of cancer. The company operates within the biotechnology, precision oncology, and nuclear medicine industries, with a strategic emphasis on integrating isotope production, radiochemistry, and targeted drug development. Perspective Therapeutics develops radiopharmaceutical candidates designed to selectively deliver radioactive isotopes to tumor cells while limiting exposure to surrounding healthy tissue.

The company’s primary revenue and value drivers are its proprietary targeted alpha therapy pipeline, isotope supply capabilities, and radiopharmaceutical manufacturing infrastructure. Perspective Therapeutics has focused on therapies using lead-212 (Pb-212), an alpha-emitting radioisotope considered promising for oncology applications due to its high-energy, short-range radiation profile. The company evolved from Cellectar Biosciences, Inc., which historically focused on phospholipid drug conjugate technology, and rebranded as Perspective Therapeutics following strategic acquisitions and a transition toward radiopharmaceutical oncology. Public filings and investor materials indicate that the company’s positioning is differentiated by its vertically integrated approach combining isotope production, drug development, and manufacturing capabilities.